Scantox Group finalizes acquisition of Gentronix Ltd, a UK-based genetic toxicology Contract Research Organization ("CRO")
Acquiring Company
Scantox Group
Acquired Company
Gentronix
Lille Skensved
Alderley EdgeBiotechnologyHealth CarePharmaceuticalBiotechnologyHealth CareGeneticsDescription
Scantox Group, together with its majority owner Impilo, has completed the acquisition of Gentronix Ltd, a UK based genetic toxicology Contract Research Organization ("CRO"). The acquisition significantly expands Scantox's service platform, enabling it to become a market-leading CRO to support pre-IND enabling studies. With this acquisition, Scantox Group now employs more than 400 people across seven European sites.
Quick answer
Scantox Group is acquiring Gentronix, announced September 9, 2024. Scantox Group is based in Lille Skensved, Zealand, Denmark.
- How much did Scantox Group pay for Gentronix?
- The deal value was not disclosed.
- What does Scantox Group do?
- Scantox Group, together with its majority owner Impilo, specializes in offering first in class lead optimization, regulatory toxicology, and CMC (Chemical, Manufacturing, Controls), formulation, and analytical services.
- Where are Scantox Group and Gentronix based?
- Scantox Group is based in Lille Skensved, Zealand, Denmark. Gentronix is based in Alderley Edge, Cheshire, United Kingdom.
- Who are the decision-makers at Scantox Group?
- Fundz holds 1 contact at Scantox Group. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Pharmaceutical and Genetics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Lupin strengthens its presence in the South African market through the acquisition of nine leading brands (October 4, 2024)
- Petauri™ completes acquisition of Brightly Network's medical communications agencies (August 14, 2024)
- Leapcure Acquires Honeybee Trials: Enhancing Patient Engagement and Research Site Solutions (August 13, 2024)
- Mankind Pharma completes acquisition of Bharat Serums and Vaccines Ltd (BSV) in a ₹13,768 crore deal, $180 (October 24, 2024)
- Merck completes acquisition of Modifi Biosciences, Inc. to advance DNA modification enabled cancer therapeutics (October 23, 2024)
- Access Genetics dba OralDNA® Labs acquires Breakthrough Point-of-Care Rapid PCR Technology from Sensible Diagnostics Inc. (October 22, 2024)
Who to call at Scantox Group, and when
When Scantox Group changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Scantox Group raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Scantox Group, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Scantox Group. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Scantox Group makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Gentronix?
Gentronix was acquired by Scantox Group, based in Lille Skensved. The deal was reported on September 9, 2024. Scantox Group, together with its majority owner Impilo, specializes in offering first in class lead optimization, regulatory toxicology, and CMC (Chemical, Manufacturing, Controls), formulation, and analytical services. Scantox Group is privately held and operates in Biotechnology.
When did Scantox Group acquire Gentronix?
Scantox Group's acquisition of Gentronix was reported on September 9, 2024. Scantox Group, together with its majority owner Impilo, has completed the acquisition of Gentronix Ltd, a UK based genetic toxicology Contract Research Organization ("CRO"). Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Gentronix do?
Gentronix is a specialist genetic toxicology contract research organization focused on providing services in genetic toxicology. The company has developed several proprietary assays to support safety testing and regulatory needs. It is privately held, operating in Biotechnology, and is based in Alderley Edge.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.